The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.
After a clinical trial showed the device was more effective than placebo, the FDA permitted marketing for the medical device that assists in the reduction of functional abdominal pain among adolescents with...
